PHASE IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER
NCT07494448 · NOT YET RECRUITING · Phase 2
We track 3 ClinicalTrials.gov studies led by Medsir. The portfolio skews toward Phase 2 (2 trials).
3 clinical trials sponsored by Medsir.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 2 | 67% |
| Phase 3 | 1 | 33% |
Medsir currently sponsors 3 clinical trials tracked on ReadTheTrial. These span Phase 2, Phase 3.
Medsir conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Medsir currently has 2 trials that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.